Figure 3 | British Journal of Cancer

Figure 3

From: Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

Figure 3

Estimates of PFS and OS.(A) PFS from week 12 in patients with melanoma who were randomly assigned to continue treatment with cabozantinib (n=13) or placebo (n=13). (B) PFS from first dose in all patients with metastatic melanoma (N=77) and in patients with uveal melanoma (n=23). (C) OS in all patients with metastatic melanoma (N=77) and in patients with uveal melanoma (n=23). HR=hazard ratio.

Back to article page